Terazosin EP Impurity A (Alfuzosin EP Impurity B, Prazosin EP Impurity A)(CAS: 23680-84-4)

Terazosin EP Impurity A (CAS: 23680-84-4) is a chemical compound identified as an impurity in pharmaceutical preparations of terazosin, alfuzosin, and prazosin. It is structurally related to these alpha-1 adrenergic receptor antagonists and is often analyzed during drug quality control to ensure compliance with safety and purity standards. Its exact chemical formula is not publicly detailed, but it is characterized as a piperazine derivative with pyrazole and trifluoroethyl groups.

Terazosin EP Impurity A (CAS: 23680-84-4) is primarily used in pharmaceutical research and quality control to identify and quantify impurities in drugs like terazosin, which treats hypertension and benign prostatic hyperplasia. It also serves as a reference standard for analytical testing, ensuring the safety and efficacy of these medications. Its role is critical in regulatory compliance and drug development processes.

Terazosin EP Impurity A (CAS: 23680-84-4) is considered safe when handled according to standard laboratory protocols and within regulated limits in pharmaceutical products. As an impurity, it is not intended for therapeutic use but is monitored to ensure minimal presence in final drug formulations. Precautions include wearing gloves, eye protection, and ensuring proper ventilation to avoid exposure. Safety standards align with OSHA and EPA guidelines for chemical handling.

Terazosin EP Impurity A (CAS: 23680-84-4) should be stored in a cool, dry place, away from light, and in a sealed container to maintain stability. It is typically kept at 2-8°C (refrigerated) to prevent degradation. Avoid exposure to moisture and heat, and ensure storage conditions comply with manufacturer specifications to preserve its chemical integrity for analytical purposes.